Edwards Lifesciences has petitioned the full Federal Circuit to narrow its interpretation of a U.S. Food and Drug Administration safe harbor that essentially permits patent infringement during drug development. The company argues that if Congress intended for the statute to be interpreted broadly, “it would have said exactly that.” The legal ramifications of this interpretation are significant for pharmaceutical companies involved in the development of new drugs, potentially impacting how patents are enforced and defended. For further details on this legal development, the original article can be accessed here.